Welcome to our dedicated page for Immunocore Holdings Plc news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings Plc stock.
Immunocore Holdings Plc (IMCR) delivers pioneering T cell receptor therapies through its ImmTAX platform, targeting complex diseases in oncology and immunology. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific advancements and corporate developments.
Access authoritative reporting on clinical trial progress, regulatory milestones, and strategic partnerships shaping Immunocore's position in biotherapeutics. The curated collection includes verified press releases covering drug candidate evaluations, financial disclosures, and technology innovations like the KIMMTRAK therapy for metastatic uveal melanoma.
Key content categories include updates on immuno-oncology research, infectious disease programs, and autoimmune treatment pipelines. Users will find analysis-neutral reporting on FDA interactions, collaborative research initiatives, and quarterly performance metrics essential for informed decision-making.
Bookmark this page for streamlined access to Immunocore's latest verified developments. Check regularly for real-time updates on groundbreaking TCR-based therapies and their impact on global healthcare solutions.
Immunocore, a Nasdaq-listed commercial-stage biotech firm specializing in immunomodulating medicines for cancer, infectious and autoimmune diseases, announced its participation in the Jefferies Global Healthcare Conference.
The event is scheduled for June 6, 2024, at 2:30 p.m. EDT.
A live webcast of the presentation will be available on the Immunocore website, with a replay accessible post-event.
Immunocore has announced the conversion of its Phase 2/3 TEBE-AM trial into a registrational Phase 3 trial to evaluate KIMMTRAK (tebentafusp-tebn) for previously treated advanced cutaneous melanoma. Following FDA consultation, all patients from the Phase 2/3 trial will be included in the Phase 3 intent-to-treat population. The Phase 3 trial will continue with three arms: KIMMTRAK monotherapy, KIMMTRAK with pembrolizumab, and a control.
This decision is expected to accelerate the time to the final overall survival analysis. The conversion was motivated by KIMMTRAK’s promising results in uveal melanoma and Phase 1 cutaneous melanoma trials. The Phase 1b study showed that KIMMTRAK, combined with checkpoint inhibitors, had a one-year overall survival rate of approximately 75% in patients with metastatic cutaneous melanoma.
Immunocore reported first quarter financial results with KIMMTRAK® net revenues of $70.3 million in Q1 2024. The company continues to expand global access with 7 additional launches since January 2024. Phase 1/2 brenetafusp clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024. Financially, the company saw a 36% increase in net product revenue, with total revenue reaching $70.3 million in Q1 2024. However, research & development expenses also grew, resulting in a net loss for the quarter. Cash and cash equivalents stood at $832.8 million as of March 31, 2024.
FAQ
What is the current stock price of Immunocore Holdings Plc (IMCR)?
What is the market cap of Immunocore Holdings Plc (IMCR)?
